Global Cancer Immunotherapies Market to Rise at 15.17% CAGR from 2016 to 2020

Published Date : May 23, 2016

Albany, New York, May 23, 2016: has recently added a new research report to its ever-increasing repository. The research report, titled “Global Cancer Immunotherapies Market 2016-2020,” reports the latest news in the global market and the upcoming developments. The researchers have used economic indicators along with primary and secondary research methodologies to compile this research report. Furthermore, the report also explains the epidemiology of the disease and the expenditure incurred on it on the global scale. The cost of various types of cancer treatments and the reimbursement policies for the same have also been discussed in this research report. For understanding the market dynamics holistically, researchers have also tried to scrutinize the deep-rooted problem of the economic burden pertaining to treating cancer and the ongoing efforts of orphan drug designation and regulatory approvals.

According to the research report, the global cancer immunotherapies market is estimated to rise at a CAGR of 15.17% from 2016 to 2020. The global cancer immunotherapies market is expected to witness an introduction of products that have single and multi-indications by the end of 2020. The researchers have used Porter’s five forces reports to highlight the threat of new entrants, the bargaining power of buyers, the threat of substitutes, the bargaining power of suppliers, and the industry rivalry prevalent in this market.

The global cancer immunotherapies market has been segmented on the basis of type and geography for a purpose of pointing out the strengths, weaknesses, opportunities, and threats impacting these segments. On the basis of type, this market is segmented into cancer monoclonal antibodies, clinical trials of cancer monoclonal antibodies, cancer vaccines, immune checkpoint inhibitors, global immune checkpoint inhibitors market, global cancer monoclonal antibodies market, non-specific immunotherapies, global cancer vaccines market, and global non-specific immunotherapies market. Geographically, this market is segmented into the Americas, Europe, the Middle East and Africa, and Asia Pacific.

For Sample Copy, click here:

The primary growth drivers in the global cancer immunotherapies market are the high prevalence of various types of cancers and the growing demand for cancer monoclonal antibodies. The rising awareness about patient assistance programs and a promising pipeline is also expected to drive this market in the near future. However, this market is being overshadowed by challenges such as the patent expiry of popular drugs, poor diagnosis or late diagnosis and screening of patients, and high research and development costs. The risk of side-effects, prohibitive pricing of drugs, and strict regulatory framework are also expected to tug this market in the downward direction.

Some of the key players profiled in this research report are GlaxoSmithKline, Amgen, F. Hoffmann-La Roche, Bristol-Myers Squibb, Merck, and Takeda Pharmaceuticals. The research report profiles these players and provides a fair assessment of the competitive landscape of the overall cancer immunotherapies market. Additionally, the report also provides an examination of financial overview, research and development activities, investment outlook, list of existing products and those in the pipeline, and business and marketing strategies of these top companies in the near future.

To order report Call Toll Free: 866-997-4948 or send an email on